Literature DB >> 33871050

Toll-like receptor 2 activation and up-regulation by high mobility group box-1 contribute to post-operative neuroinflammation and cognitive dysfunction in mice.

Fei Lin1,2, Weiran Shan1, Yuxin Zheng1,3, Linghui Pan2, Zhiyi Zuo1.   

Abstract

Post-operative cognitive dysfunction (POCD) is common and is associated with poor clinical outcome. Toll-like receptor (TLR) 3 and 4 have been implied in the development of POCD. The role of TLR2, a major brain TLR, in POCD is not clear. High mobility group box-1 (HMGB1) is a delayed inflammatory mediator and may play a role in POCD. The interaction between HMGB1 and TLRs in the perioperative period is not known. We hypothesize that TLR2 contributes to the development of POCD and that HMGB1 regulates TLR2 for this effect. To test these hypotheses, 6- to 8-week old male mice were subjected to right carotid artery exposure under isoflurane anesthesia. CU-CPT22, a TLR1/TLR2 inhibitor, at 3 mg/kg was injected intraperitoneally 30 min before surgery and 1 day after surgery. Glycyrrhizin, a HMGB1 antagonist, at 200 mg/kg was injected intraperitoneally 30 min before surgery. Mice were subjected to Barnes maze and fear conditioning tests from 1 week after surgery. Hippocampus and cerebral cortex were harvested 6 hr or 12 hr after the surgery for Western blotting, ELISA, immunofluorescent staining, and chromatin immunoprecipitation. There were neuroinflammation and impairment of learning and memory in mice with surgery. Surgery increased the expression of TLR2 and TLR4 but not TLR9 in the brain of CD-1 male mice. CU-CPT22 attenuated surgery-induced neuroinflammation and cognitive impairment. Similarly, surgery induced neuroinflammation and cognitive dysfunction in C57BL/6J mice but not in TLR2-/- mice. TLR2 staining appeared in neurons and microglia. Surgery increased HMGB1 in the cell nuclei of the cerebral cortex and hippocampus. Glycyrrhizin ameliorated this increase and the increase of TLR2 in the hippocampus after surgery. Surgery also increased the amount of tlr2 DNA precipitated by an anti-HMGB1 antibody in the hippocampus. Our results suggest that TLR2 contributes to surgery-induced neuroinflammation and cognitive impairment. HMGB1 up-regulates TLR2 expression in the hippocampus after surgery to facilitate this contribution. Thus, TLR2 and HMGB1 are potential targets for reducing POCD.
© 2021 International Society for Neurochemistry.

Entities:  

Keywords:  high mobility group box-1; neuroinflammation; post-operative cognitive dysfunction; toll-like receptors 2

Mesh:

Substances:

Year:  2021        PMID: 33871050      PMCID: PMC8895530          DOI: 10.1111/jnc.15368

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  53 in total

1.  Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats.

Authors:  Junfeng Zhang; Hongying Tan; Wei Jiang; Zhiyi Zuo
Journal:  Anesthesiology       Date:  2014-10       Impact factor: 7.892

Review 2.  Targeting HMGB1 in the treatment of sepsis.

Authors:  Haichao Wang; Mary F Ward; Andrew E Sama
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

3.  The role of the TLR4 signaling pathway in cognitive deficits following surgery in aged rats.

Authors:  Yi Wang; Huijuan He; Dan Li; Wenjing Zhu; Kaiming Duan; Yuan Le; Yan Liao; Yangwen Ou
Journal:  Mol Med Rep       Date:  2013-02-18       Impact factor: 2.952

4.  Discovery of small-molecule inhibitors of the TLR1/TLR2 complex.

Authors:  Kui Cheng; Xiaohui Wang; Shuting Zhang; Hang Yin
Journal:  Angew Chem Int Ed Engl       Date:  2012-09-11       Impact factor: 15.336

Review 5.  Extracellular role of HMGB1 in inflammation and sepsis.

Authors:  H Wang; H Yang; K J Tracey
Journal:  J Intern Med       Date:  2004-03       Impact factor: 8.989

6.  Attenuation of noisy environment-induced neuroinflammation and dysfunction of learning and memory by minocycline during perioperative period in mice.

Authors:  Fei Lin; Yuxin Zheng; Linghui Pan; Zhiyi Zuo
Journal:  Brain Res Bull       Date:  2020-03-21       Impact factor: 4.077

7.  TLR2 has a detrimental role in mouse transient focal cerebral ischemia.

Authors:  Gina Ziegler; Denise Harhausen; Claudia Schepers; Olaf Hoffmann; Christina Röhr; Vincent Prinz; Janett König; Hans Lehrach; Wilfried Nietfeld; George Trendelenburg
Journal:  Biochem Biophys Res Commun       Date:  2007-05-30       Impact factor: 3.575

8.  Electroacupuncture Alleviates Postoperative Cognitive Dysfunction in Aged Rats by Inhibiting Hippocampal Neuroinflammation Activated via Microglia/TLRs Pathway.

Authors:  Pei-Pei Feng; Pu Deng; Li-Hua Liu; Qi Ai; Jie Yin; Zhe Liu; Gai-Mei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2017-06-08       Impact factor: 2.629

9.  Neuroinflammatory Dynamics Underlie Memory Impairments after Repeated Social Defeat.

Authors:  Daniel B McKim; Anzela Niraula; Andrew J Tarr; Eric S Wohleb; John F Sheridan; Jonathan P Godbout
Journal:  J Neurosci       Date:  2016-03-02       Impact factor: 6.167

10.  Critical role of matrix metallopeptidase 9 in postoperative cognitive dysfunction and age-dependent cognitive decline.

Authors:  Jiangjiang Bi; Weiran Shan; Ailin Luo; Zhiyi Zuo
Journal:  Oncotarget       Date:  2017-02-20
View more
  9 in total

Review 1.  Toll-like receptor-mediated neuroinflammation: relevance for cognitive dysfunctions.

Authors:  Silvia Squillace; Daniela Salvemini
Journal:  Trends Pharmacol Sci       Date:  2022-06-23       Impact factor: 17.638

2.  Network Biology Approaches to Uncover Therapeutic Targets Associated with Molecular Signaling Pathways from circRNA in Postoperative Cognitive Dysfunction Pathogenesis.

Authors:  Piplu Bhuiyan; G S Chuwdhury; Zhaochu Sun; Yinan Chen; Hongquan Dong; Fee Faysal Ahmed; Li Nana; Md Habibur Rahman; Yanning Qian
Journal:  J Mol Neurosci       Date:  2022-07-06       Impact factor: 2.866

Review 3.  Neuroinflammation as the Underlying Mechanism of Postoperative Cognitive Dysfunction and Therapeutic Strategies.

Authors:  Zhichao Li; Youzhuang Zhu; Yihan Kang; Shangyuan Qin; Jun Chai
Journal:  Front Cell Neurosci       Date:  2022-03-28       Impact factor: 5.505

4.  NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation.

Authors:  Agata Habas; Srinivasa Reddy Natala; Jon K Bowden-Verhoek; Emily M Stocking; Diana L Price; Wolfgang Wrasidlo; Douglas W Bonhaus; Martin B Gill
Journal:  Int J Inflam       Date:  2022-02-27

5.  Characterization of Immune-Related Genes and Immune Infiltration Features in Epilepsy by Multi-Transcriptome Data.

Authors:  Yunqi Hou; Zhen Chen; Liping Wang; Yingxin Deng; Genglong Liu; Yongfen Zhou; Haiqin Shi; Xiangqun Shi; Qianhua Jiang
Journal:  J Inflamm Res       Date:  2022-05-05

6.  Electroacupuncture Ameliorates Tibial Fracture-Induced Cognitive Dysfunction by Elevating α7nAChR Expression and Suppressing Mast Cell Degranulation in the Hippocampus of Rats.

Authors:  Yudi Zhou; Cheng Hu; Chenlu Mao; Sha Li; Yaomei Cui; Yanning Qian
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-12       Impact factor: 2.650

7.  Monocyte NLRP3-IL-1β Hyperactivation Mediates Neuronal and Synaptic Dysfunction in Perioperative Neurocognitive Disorder.

Authors:  Kai Chen; Qiuping Hu; Zhongcong Xie; Guang Yang
Journal:  Adv Sci (Weinh)       Date:  2022-03-28       Impact factor: 17.521

8.  TLR3 deletion inhibits programmed necrosis of brain cells in neonatal mice with sevoflurane-induced cognitive dysfunction.

Authors:  Qi Zhang; Yanan Li; Jiaxu Yu; Chunping Yin; Junfei Guo; Juan Zhao; Qiujun Wang
Journal:  Aging (Albany NY)       Date:  2022-06-06       Impact factor: 5.955

Review 9.  Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild-moderate COVID-19 and prevention of post-COVID cognitive impairment.

Authors:  Adel A Gomaa; Yasmin A Abdel-Wadood; Mohamed A Gomaa
Journal:  Inflammopharmacology       Date:  2022-09-22       Impact factor: 5.093

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.